Thermal burn injury is the most contested of the FDA-recognized HBOT indications. The UHMS endorses it, the Cochrane review found the evidence too thin to settle, and most US burn centers do not use HBOT.
This page lays out the strongest case for HBOT in burns, the limits of that case, and why good burn surgeons reach different views on the same data.
Quick Facts
| Field | Value |
|---|---|
| FDA approval status | Recognized indication (one of 14) |
| UHMS classification | Tier 1 — approved for severe burns |
| Typical protocol | 2.0-2.4 ATA, 90 min, 2-3 sessions/day initially, 10-30 sessions total |
| Medicare coverage | Limited — case-by-case under NCD 20.29, 2017 |
| Insurance prior auth | Always required; many plans deny |
| Evidence grade | GRADE C (positive case series, no large RCT) |
The evidence
The burn HBOT literature has more case series than randomized trials. The two best-known reviews reach different conclusions.
The Villanueva Cochrane review, CD004727 2004 pooled two trials totaling 125 patients. The review concluded that the evidence was too thin to support or refute HBOT in burn care. This is still the most-cited Cochrane finding on burn HBOT.
The Cianci review, J Burn Care Res 2013 PMID 23397872 reached a different conclusion. The authors pooled animal and clinical data and argued for HBOT benefit on mortality, hospital stay, surgical count, and cost. The review reads as a strong endorsement.
The Cianci chapter in the UHMS ECCHO 2016 reference restates the case for HBOT in burns.
A 2022 PMC review on therapeutic outcomes in burn HBOT examined a single-center experience. The conclusion was that HBOT reduced mortality and length of stay in severe burns when started within 24 hours.
A more recent 2024 systematic review in J Burn Care Res found that the evidence base remains thin. Sample sizes are small and trial designs vary. The signal is suggestive but not definitive.
The StatPearls 2024 reference on hyperbaric burn treatment summarizes the clinical state without taking a strong position.
The pattern: animal data is positive. Single-center clinical series are positive. Pooled trial data is too thin to settle the question.
Mechanism of action
Burn injury creates three zones around the wound. The center is dead tissue, ringed by a zone of stasis where tissue is just barely alive. The outer zone has swelling but live cells.
The zone of stasis is the target for HBOT. Without intervention, much of that tissue converts to full-thickness loss over the first 48 hours. HBOT aims to keep it alive.
Hyperbaric oxygen helps the zone of stasis in several ways. It raises plasma oxygen high enough to feed tissue with poor blood flow, cuts swelling by lowering capillary leak, and boosts neutrophil killing of bacteria.
HBOT also blunts the body-wide swelling response after major burns. Cytokines drop. The metabolic stress on the body falls.
The mechanism is well-mapped. The clinical question is whether HBOT gives enough margin over modern burn care — early surgery, skin grafts, fluid support, and infection control — to justify the add-on.
Typical protocol
The most common burn HBOT protocol is 2.0 to 2.4 ATA for 90 minutes. Sessions are given two to three times per day in the first 48 hours, then daily.
Total session counts run 10 to 30 depending on burn severity. Severe burns with delayed presentation may need fewer sessions. Patients who start HBOT immediately get the most benefit per session, in the Cianci framework.
The challenge is that burn patients are often critically ill. Many are intubated on ventilators. Chamber treatment of ventilated patients requires a multiplace chamber and trained respiratory staff — few centers have this setup.
Air breaks are used during longer sessions to limit oxygen toxicity. This matters more in burn patients because of fluid shifts and metabolic stress.
Insurance and cost
Medicare covers thermal burns under NCD 20.29, 2017, but the language is narrower than for other uses. Coverage is case-by-case and asks for proof of severity.
Cost per session in critical burn care is high. Multiplace chamber sessions for vented patients can run $3,000 to $8,000 each. A 20 to 30 session course adds $60,000 to $240,000 to a hospital stay that is already costly.
Commercial insurance varies widely. Many plans deny burn HBOT claims unless the patient is treated at a center with set burn HBOT rules.
Billing shapes practice. Burn centers without set HBOT rules tend not to pursue HBOT because the payment path is unclear.
Where to get it
Burn HBOT is delivered at a small number of US burn centers with on-site hyperbaric chambers. Most burn centers do not have hyperbaric capacity. Transfer of a critically ill burn patient to a hyperbaric center is rarely done.
The UHMS accredited facility directory, current 2026 lists chambers but not burn-specific capability. Patients should ask burn surgeons whether their center uses HBOT.
For chamber clearance details, see our FDA-cleared chambers list. Burn HBOT typically requires multiplace chambers that can hold an ICU bed and respiratory equipment.
The geographic concentration is striking. A handful of US burn centers do most of the burn HBOT. The rest of the country effectively does not have this option, even where the indication is clinically reasonable.
Limitations and contraindications
Hemodynamic instability is the main limit in burn HBOT. A patient with unstable blood pressure or arrhythmias is not a chamber candidate. The chamber environment limits acute intervention.
Untreated pneumothorax is an absolute limit. Burn patients with chest trauma or thoracic burns often need chest imaging before chamber use.
Severe inhalation injury with airway swelling is a relative limit. The chamber environment can worsen airway control if rapid intervention is needed.
The harder limit is logistics. Chamber treatment of a critically ill burn patient ties up the chamber, multiple staff, and ICU resources for 90 minutes per session. Many burn programs simply cannot resource this.
Late presentation reduces benefit. The Cianci framework argues that HBOT benefit drops sharply after 24 hours. By the time many burn centers consider HBOT referral, the window has narrowed.
Active research
ClinicalTrials registry studies on burn HBOT, current 2026 include trials on early-presentation protocols, pediatric burn HBOT, and outcomes after smoke inhalation.
The active research focus has shifted toward selection — which burn patients benefit most, at which severity, and at what timing. The goal is to identify the subgroup where the case is strongest, since blanket use is not supported by trial data.
Active questions include the role of HBOT in chemical burns (separate from thermal), the value of pre-grafting HBOT to improve graft take, and whether HBOT helps with post-burn scar maturation.
How this compares to off-label HBOT uses
Burns sit in a gray zone. The indication is UHMS-recognized and FDA-acknowledged, but the evidence base is real and thin. The Cochrane review stays neutral, and most US burn centers do not use HBOT.
This is still different from off-label wellness HBOT. Burn HBOT is delivered in burn centers under critical care protocols for a defined patient group. Off-label HBOT for long COVID or anti-aging is delivered in wellness clinics with no comparable case series, no Cochrane review, and no FDA recognition.
For context on how off-label HBOT marketing diverges from clinical evidence, read our analysis of institutional silence on HBOT and our breakdown of marketing-driven HBOT claims.
The honest summary: burn HBOT is a recognized but contested indication. Both the proponents (Cianci and similar) and the skeptics (Cochrane) are working from real but limited data.
Frequently asked questions
Do all burn centers offer HBOT?
No. Most US burn centers do not. The handful that do tend to have on-site multiplace chambers and dedicated burn HBOT protocols. Ask the receiving burn surgeon whether HBOT is part of their standard practice.
How fast does HBOT need to start after a burn?
The Cianci framework argues that within 24 hours gives the most benefit. The mechanism (saving the zone of stasis) operates in the first 48 hours. Delayed HBOT may still help with infection control and wound healing, but with smaller effect size.
Is HBOT a substitute for early excision and grafting?
No. Modern burn care relies on early surgical excision of dead tissue and skin grafting. HBOT is an adjunct, not a replacement. It aims to reduce the depth of injury before excision.
Can a soft-shell wellness chamber treat a burn?
No. Burn HBOT requires 2.0 to 2.4 ATA in a multiplace chamber capable of supporting critical care. Soft-shell chambers do not reach those pressures and are not equipped for ICU-level patient care.
Why is the Cochrane review still cited as inconclusive?
Because no large randomized trial has been done since 2004. The pooled trials had small samples and methodological limits. Until a larger trial is run, the Cochrane summary stays where it is.
Sources
- Villanueva Cochrane Review, CD004727 2004
- Cianci J Burn Care Res 2013, PMID 23397872
- Cianci UHMS ECCHO chapter, 2016
- PMC Therapeutic Outcomes Review, 2022
- J Burn Care Res Systematic Review, 2024
- StatPearls Hyperbaric Burn Treatment, 2024
- CMS NCD 20.29 Hyperbaric Oxygen Therapy, 2017
- UHMS accredited facility directory, current 2026
Medical disclaimer
This page is medical journalism, not medical advice. Severe thermal burns are a critical-care emergency that should be managed at a verified burn center. HBOT treats selected burn cases as an adjunct to standard care; it does not replace early surgical care, fluid resuscitation, or infection control. Talk to a burn surgeon about treatment decisions.